Global Radiopharmaceutical Sales Market Report 2020

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
In the next few years, Radiopharmaceuticals industry will maintain increasing at a relatively high growth rate. Investors are still optimistic about this area; the future will still have more new investment enter the field.
The classification of Radiopharmaceuticals includes Diagnostic Radioisotopes, Therapeutic Radioisotopes. The revenue proportion of Diagnostic Radioisotopes in 2016 is about 77%, and the proportion is in decreasing trend from 2012 to 2017. The Therapeutic Radioisotopes is enjoying more and more market share.
Radiopharmaceuticals are widely used in Oncology, Cardiology and Other disease diagnosis and treatment. The most of radiopharmaceuticals is used in Oncology, and the sales proportion in 2016 is about 60%.

Market Analysis and Insights: Global Radiopharmaceutical Market
The global Radiopharmaceutical market size is projected to reach US$ 10520 million by 2026, from US$ 6410.1 million in 2020, at a CAGR of 8.6% during 2021-2026.

Global Radiopharmaceutical Scope and Market Size
The global Radiopharmaceutical market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Radiopharmaceutical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Radiopharmaceutical market is segmented into
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other

Segment by Application, the Radiopharmaceutical market is segmented into
Oncology
Cardiology
Other

The Radiopharmaceutical market is analysed and market size information is provided by regions (countries). Segment by Application, the Radiopharmaceutical market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Radiopharmaceutical Market Share Analysis
Radiopharmaceutical market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Radiopharmaceutical business, the date to enter into the Radiopharmaceutical market, Radiopharmaceutical product introduction, recent developments, etc.

The major vendors covered:
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea